Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding insider trading activity rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific securities transaction involving American Depositary Shares (ADSs).
Material Changes and Transaction Details
The filing reports an increase in the notional interest in GSK ADSs by Dr. K. Slaoui, a person closely associated with Dr. M. M. Slaoui (Chairman, Global Vaccines). The transaction occurred on July 14, 2016, resulting from the re-investment of dividends paid to shareholders under the Company's 2009 Performance Share Plan.
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Type: Dividend Re-investment
- Transaction Price: $43.87 per ADS
- Total Volume: 74.827 ADSs
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, risk factors, contingencies, or unusual items. It is a statutory disclosure of a specific executive transaction.
Investor Verification Points
- Verify the total number of ADSs held by Dr. K. Slaoui and Dr. M. M. Slaoui following this transaction.
- Confirm the terms of the 2009 Performance Share Plan regarding dividend re-investment.
- Check the market price of GSK ADSs on July 14, 2016, to validate the reported transaction price of $43.87.